Nasdaq · Healthcare
MACROGENICS INC (MGNX)
As-reported financials and recent SEC filings for MACROGENICS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$149.5M
Net income
$-74.6M
Net margin
-49.9%
Diluted EPS
$-1.18
ROE
-134.2%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $149.5M | $150.0M | $58.7M | $151.9M | $77.4M |
| Gross profit | — | — | — | — | — |
| Operating income | $-72.8M | $-110.6M | $-168.2M | $-121.4M | $-202.8M |
| Net income | $-74.6M | $-67.0M | $-9.1M | $-119.8M | $-202.1M |
| Diluted EPS | $-1.18 | $-1.07 | $-0.15 | $-1.95 | $-3.37 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
SCHEDULE 13G2026-06-05
View on EDGAR →42026-05-20
View on EDGAR →42026-05-20
View on EDGAR →42026-05-20
View on EDGAR →42026-05-20
View on EDGAR →42026-05-20
View on EDGAR →42026-05-20
View on EDGAR →42026-05-20
View on EDGAR →Largest Healthcare peers
Go deeper on MGNX
Search MACROGENICS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.